CLIMB BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 96.08K shares.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 1.64K shares.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 12.46K shares, a 94.39% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 404.10K shares, a 12.09% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 21.34K shares, a 99.20% decline from fiscal 2024.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 2.68M shares, a 140.76% increase from fiscal 2023.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.11M shares.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 96.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | 1.64K shares 10-Q · filed 2026-05-07 | |
| 2025-12-31 | 21.34K shares 10-K · filed 2026-03-05 | |
| 2024-12-31 | 12.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 2.68M shares 10-K · filed 2025-03-25 |
| 2024-09-30 | 404.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 2.89M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 2.25M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 2.94M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 11.00K shares 10-Q · filed 2024-05-15 | 716.32K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 222.11K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 1.11M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 459.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 889.40K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 23.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 429.72K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 406.19K shares 10-Q · filed 2023-05-11 | 406.19K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 0.00 shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 19.78K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 19.78K shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-16 | |
| 2021-12-31 | 19.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | 79.25K shares 10-K · filed 2022-03-07 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |